Business
SEQUANA MEDICAL ANNOUNCES THE ISSUANCE OF A SUBSCRIPTION REQUEST NOTICE UNDER THE SHARE SUBSCRIPTION FACILITY AGREEMENT WITH GEM
Ghent, Belgium, Feb. 02, 2026 (GLOBE NEWSWIRE) -- PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION2 February 2026, 6:00 pm CET Ghent, Belgium, 2 February 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a subscription request notice in accordance with the terms of the share subscription facility agreement (the "Fac
About this update from Sequana Medical N.v
[{"type":"image","alt":"Sequana Medical NV","displaySize":"","headline":null,"caption":"Sequana Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/I6pT.8uzi87Vh1qGIu6GAg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64}},"lazy":false},{"type":"text","content":"Ghent, Belgium, Feb. 02, 2026 (GLOBE NEWSWIRE) -- ","length":49,"tagName":"p"},{"type":"text","content":"PRESS RELEASEREGULATED INFORMATION – INSIDE INFORMATION2 February 2026, 6:00 pm CET","length":85,"tagName":"p"},{"type":"text","content":"Ghent, Belgium, 2 February 2026 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, announces today that it issued a subscription request notice in accordance with the terms of the share subscription facility agreement (the "Facility") entered into on 17 March 2025 between the Company and GEM Global Yield LLC SCS ("GEM"). Under the terms of the Facility, GEM has agreed, subject to certain conditions, to commit an amount of up to EUR 20 million in cash (with the Company's option to increase the commitment to up to EUR 60 million in cash, once the aforementioned EUR 20 million has been drawn down), within a maximum term of three years, in exchange for new shares in the Company and subject to certain share lending arrangements being in place. For more information about the Facility, reference is made to the Company's press release dated 18 March 2025 (which can be accessed here).","length":1075,"tagName":"p"},{"type":"text","content":"The new subscription request notice is expected to be settled into new shares on or around 4 March 2026. The number of new shares the Company has requested GEM to subscribe for amounts to up to 2,999,900 shares in the Company (the "Draw Down Amount"). The issue price of the relevant new shares to be issued will be equal to 90% of the average volume weighted average price (VWAP) of the Company's shares during a forward-looking pricing period and will b...